Industry Insights A tough year 10 December 2025

https://rarerevolutionmagazine.com/a-tough-year/ 2025 has felt a tough year for the biotech and pharmaceutical industry. Although we’ve seen approval in the UK of some new innovations in the rare disease world, uncertainties around President Donald Trump and USA policy, combined with fraught and unresolved VPAG (2024 Voluntary Scheme on Pricing, Access and Growth) negotiations, have caused organisations to pause—giving way for debate on viability of launching in the UK, review of and in some cases deprioritising/removing investment here, plus more subtly reductions on spend and recruitment. Meanwhile we all wait to see where things land. Changes in research and development (R&D) investment and the FDA (Food and Drug Administration) in the US also sent ripples through the community. Sadly, the consequence of this results in delayed access to new innovations for us the general public. For the rare disease community especially, this is devastating as many have no current treatment, research is precious and time matters. https://rarerevolutionmagazine.com/category/rare-insights/industry-insights/